Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCF1 | P14598 | 1/20 | 0.41 |
| ▸ | MGLL | Q99685 | 2/20 | 0.34 |
| ▸ | PHGDH | O43175 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | QDPR | P09417 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL8692037 | 0.84 | NCF1 (0.37) | NCF1SMN1; SMN2KDM4EMAPTAPOBEC3G | |
| SCHEMBL15325087 | 0.77 | SMN1; SMN2 (0.31) | SMN1; SMN2 | |
| SCHEMBL13223293 | 0.75 | SMN1; SMN2 (0.30) | SMN1; SMN2 | |
| SCHEMBL17779823 | 0.75 | SMN1; SMN2 (0.30) | SMN1; SMN2 | |
| SCHEMBL19622413 | 0.75 | NCF1 (0.41) | NCF1SMN1; SMN2ALDH1A1HTTLMNA | |
| SCHEMBL803894 | 0.75 | NOS2 (0.57) | NCF1SMN1; SMN2ALDH1A1HTTLMNA | |
| SCHEMBL274448 | 0.75 | SMN1; SMN2 (0.59) | NCF1SMN1; SMN2KDM4EALDH1A1GAA | |
| SCHEMBL11039671 | 0.75 | SMN1; SMN2 (0.59) | NCF1SMN1; SMN2KDM4EALDH1A1GAA | |
| SCHEMBL3123800 | 0.75 | ATM (0.34) | SMN1; SMN2KDM4EMAPTAPOBEC3G | |
| SCHEMBL467970 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11873298-B2 | Compounds and uses thereof | JANSSEN PHARMACEUTICA NV (BE) | 2024-01-16 | — | — | US | disclosed |
| EP-3122746-B1 | PHENYLPIPERIDINECARBOXAMIDE DERIVATIVES AS FUNGICIDES | BAYER CROPSCIENCE AG (DE) | 2018-04-25 | — | — | EP | disclosed |
| US-9771357-B2 | ALXR agonist compound | ONO PHARMACEUTICAL CO., LTD. (JP) | 2017-09-26 | — | — | US | disclosed |
| US-20170137417-A1 | PHENYLPIPERIDINECARBOXAMIDE DERIVATIVES AS FUNGICIDES | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2017-05-18 | — | — | US | disclosed |
| US-20170137417-A1 | PHENYLPIPERIDINECARBOXAMIDE DERIVATIVES AS FUNGICIDES | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2017-05-18 | — | — | US | disclosed |
| CN-103403002-B | Thiazolylphenyl-benzderivativesido derivativesido as inhibitors of kinases | 内尔维阿诺医学科学有限公司 | 2016-06-22 | — | — | CN | disclosed |
| US-9357779-B2 | Ketoheteroarylpiperdine and -piperazine derivatives as fungicides | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2016-06-07 | — | — | US | disclosed |
| US-20160145249-A1 | ALXR AGONIST COMPOUND | ONO PHARMACEUTICAL CO., LTD. (JP) | 2016-05-26 | — | — | US | disclosed |
| EP-2678336-B1 | THIAZOLYLPHENYL-BENZENESULFONAMIDO DERIVATIVES AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2016-04-20 | — | — | EP | disclosed |
| US-9220266-B2 | Ketoheteroarylpiperidine and -piperazine derivatives as fungicides | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-12-29 | — | — | US | disclosed |
| US-20080306114-A1 | Human G Protein-Coupled Receptor and Modulators Thereof for the Treatment of Hyperglycemia and Related Disorders | ARENA PHARMACEUTICALS, INC (US) | 2008-12-11 | — | — | US | disclosed |
| US-20070231263-A1 | Human G protein-coupled receptor and modulators thereof for the treatment of hyperglycemia and related disorders | ARENA PHARMACEUTICALS, INC. | 2007-10-04 | — | — | US | disclosed |
| US-7199124-B2 | JNK inhibitor | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-04-03 | — | — | US | disclosed |
| US-20050080113-A1 | Medicinal compositions | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-04-14 | — | — | US | disclosed |
| US-20040063946-A1 | Jnk inhibitor | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-04-01 | — | — | US | disclosed |
| EP-1402900-A1 | MEDICINAL COMPOSITIONS | Takeda Chemical Industries, Ltd. (JP) | 2004-03-31 | — | — | EP | disclosed |
| US-20040053973-A1 | Substituted 1,3-thiazole compounds, their production and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-03-18 | — | — | US | disclosed |
| EP-1364949-A1 | JNK INHIBITOR | Takeda Chemical Industries, Ltd. (JP) | 2003-11-26 | — | — | EP | disclosed |
| EP-1268474-A2 | SUBSTITUTED 1,3-THIAZOLE COMPOUNDS, THEIR PRODUCTION AND USE | Takeda Chemical Industries, Ltd. (JP) | 2003-01-02 | — | — | EP | disclosed |
| WO-2001074811-A2 | SUBSTITUTED 1,3-THIAZOLE COMPOUNDS, THEIR PRODUCTION AND USE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050080113-A1 | Medicinal compositions | TNF, TRAF6, MMP8 | NCF1 78/4885MGLL 2266/4885PHGDH 1936/4885 |
| US-20070231263-A1 | Human G protein-coupled receptor and modulators thereof for the treatment of hyperglycemia and related disorders | GPR119, GCGR, GLP1R | NCF1 3415/4885MGLL 583/4885PHGDH 942/4885 |
| US-20040053973-A1 | Substituted 1,3-thiazole compounds, their production and use | MAPK1, MAP4K2, MAPK4 | NCF1 2007/4885MGLL 4720/4885PHGDH 1299/4885 |
| US-11873298-B2 | Compounds and uses thereof | NLN, ACHE, CLN6 | NCF1 3227/4885MGLL 3982/4885PHGDH 2767/4885 |
| US-20080306114-A1 | Human G Protein-Coupled Receptor and Modulators Thereof for the Treatment of Hyperglycemia and Related Disorders | GPR119, GCGR, GLP1R | NCF1 3415/4885MGLL 583/4885PHGDH 942/4885 |
| US-20040063946-A1 | Jnk inhibitor | MAPK1, MAPK7, MAP3K7 | NCF1 401/4885MGLL 4734/4885PHGDH 1563/4885 |
| US-20170137417-A1 | PHENYLPIPERIDINECARBOXAMIDE DERIVATIVES AS FUNGICIDES | CYP1A1, PNPO, PADI1 | NCF1 1165/4885MGLL 4753/4885PHGDH 2069/4885 |
| US-20160145249-A1 | ALXR AGONIST COMPOUND | MRGPRX2, MRGPRX1, MRGPRX4 | NCF1 597/4885MGLL 2841/4885PHGDH 3650/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.